Simufilam IND Hold Lifted: Mechanism Opacity Caps a Necessary-But-Insufficient Milestone

FDA Lifts Clinical Hold on Simufilam for TSC-Related Epilepsy

Filana Therapeutics announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold on its investigational new drug (IND) application for simufilam. This decision enables the company to initiate a planned Phase 2a proof-of-concept study in patients aged 12 to 55 with Tuberous Sclerosis Complex (TSC)-related epilepsy. Patient screening for the study is expected to begin by the first quarter of 2027. Filana Therapeutics has completed key trial-readiness activities, including engaging a clinical research organization, identifying clinical trial sites, and recruiting potential investigators, positioning the company to progress expeditiously toward site initiation and patient enrollment.

• The FDA's decision to lift the clinical hold on simufilam's IND application clears the path for Filana Therapeutics to initiate its Phase 2a study in TSC-related epilepsy. This allows the company to move forward with patient screening, expected to begin in Q1 2027, following the completion of essential trial-readiness activities during the hold period.
• The planned Phase 2a study is a 16-week, multicenter, randomized, double-blind trial evaluating two doses of simufilam in 40 subjects aged 12-55 with refractory TSC-related seizures across 13 U.S. sites. The study aims to assess safety, tolerability, pharmacokinetics, and various seizure-related measures, with an optional 48-week extension study for completers.
• Simufilam, an oral small molecule modulating the filamin A protein, is supported by preclinical findings showing reduced seizure frequency in mouse models of TSC-related pathology. This development addresses a significant unmet need, as 80-90% of TSC patients experience epilepsy, and over 60% remain refractory to current antiepileptic therapies, affecting approximately 45,000 people in the U.S.

Simufilam's Safety Profile: A Foundation for Advancing Development

Early clinical trials of simufilam demonstrated improvements in experimental CSF biomarkers and indications of cognitive improvement in mild AD patients at 1 year. The drug's mechanism centers on disrupting the filamin A–α7 nicotinic acetylcholine receptor (α7nAChR) interaction, which reduces Aβ's high-affinity binding to α7nAChR and suppresses Aβ's toxic signaling — a target that had previously posed significant challenges for direct pharmacological competition given the ultra-high-affinity interaction between Aβ and α7nAChR in the AD brain.

Simufilam is currently in Phase 3 clinical trials as a disease-modifying treatment for AD. The knowledge base does not have sufficient information on this aspect.

Addressing the Persistent Challenges in TSC-Related Epilepsy Treatment

TSC-related epilepsy presents a complex therapeutic landscape where seizure control alone is insufficient to address the full burden of disease. The neurological phenotype is variable and unpredictable, and early refractory seizures — infantile spasms in particular — are associated with poor neurological outcomes, underscoring the urgency of timely and effective intervention.

• Refractory seizures and limited first-line options: For infantile spasms, vigabatrin is the first-line treatment, with steroids and classic antiepileptic drugs (AEDs) suitable for second line. For most other seizure types, treatment is similar to that for patients without TSC, including the use of novel AEDs, although limited data are available. Uncontrolled seizures are associated with higher rates of intellectual disability and more pronounced TSC-associated neuropsychiatric disorders (TAND) manifestations compared to controlled seizures.

• Evolving but still uncertain role of mTOR inhibitors and cannabidiol: Treatment with everolimus, an inhibitor of the mechanistic target of rapamycin (mTOR), reduced seizures when compared to placebo, and mTOR inhibitors may have an overall disease-modifying effect. However, the role of cannabidiol in the treatment of refractory seizures in TSC is yet to be established, and data on long-term safety of these agents are needed.

• Neuropsychiatric comorbidities remain inadequately addressed: Despite advances in treatment options, including mTOR inhibitors and newer antiepileptic drugs, unmet needs remain in the comprehensive care of TSC patients. Autism spectrum disorder (ASD) was reported in 42% of one cohort, and intellectual disability was prevalent at 67.6%, yet the relationship between ASD, TSC, and epilepsy remains complex and requires further investigation.

• Gaps in preventive intervention evidence: Final recommendations on preventive treatment with vigabatrin were pending results from two multicenter trials — PREVeNT (NCT02849457) in the US and EPISTOP (NCT02098759) in Europe — reflecting that the evidence base for early preventive strategies was still being established at the time of reporting.

• Need for multidisciplinary and individualized care: Optimizing seizure control is a clear priority, but equally important is addressing the cognitive and behavioral components of TAND. Early intervention with tailored, multidisciplinary approaches — including neurology, psychiatry, psychology, and educational specialists — is required, and these approaches must be individualized to each patient's unique set of challenges, emphasizing not only seizure control but also psychosocial support and educational adaptation.

Exploring Novel Targets: Simufilam's Approach to TSC-Related Epilepsy

Recent research into TSC-related epilepsy has focused on multiple converging molecular pathways, with particular emphasis on the mTOR signaling axis and gene-level interventions that address the root cause of TSC pathology.

• mTORC1 and mTORC2 dual targeting: Hyperactivity of both mTORC1- and mTORC2-dependent signaling has been shown to cause epilepsy downstream of somatic PTEN loss. Spontaneous seizures and epileptiform activity persisted despite inactivation of either complex alone, but inactivating both mTORC1 and mTORC2 normalized pathology — indicating that targeted therapies should aim to reduce activity of both complexes.

• AAV-mediated gene replacement for TSC2: A "condensed" form of human tuberin (cTuberin) delivered via AAV9 intravenously extended mean survival from 58 days to 462 days in a TSC2 mouse model, with concurrent reduction in brain pathology. This demonstrates the potential of a single intravenous injection of AAV9-cTuberin to treat life-threatening TSC2 lesions.

• AAV-mediated gene replacement for TSC1: Intracerebroventricular delivery of an AAV vector (serotype rh8) expressing hamartin in a TSC1 neuronal knockout model extended mean survival from 22 days to 52 days, with improved weight gain, motor behavior, normalization of neuron size, and decreased markers of mTOR activation.

• 4E-BP2-dependent translation in parvalbumin neurons: Ablation of 4E-BP2, a translational repressor downstream of mTORC1, increases seizure susceptibility, and a mouse model harboring a human PIK3CA mutation that enhances PI3K-AKT activity selectively in parvalbumin neurons shows susceptibility to PTZ-induced seizures — identifying 4E-BP2 and parvalbumin neuron mTORC1-dependent translation as targets in epileptogenesis.

The Evolving Treatment Landscape for TSC-Related Epilepsy

The mTOR inhibitor everolimus has established itself as a cornerstone of adjunctive therapy for TSC-associated refractory seizures, supported by long-term data from the EXIST-3 programme. In the extension phase, the response rate (≥50% reduction in seizure frequency) rose from 31% (95% CI, 26.2–36.1) at week 18 to 57.7% (95% CI, 49.7–65.4) at 2 years, with a corresponding median percentage reduction in seizure frequency of 56.9% (95% CI, 50–68.4) at 2 years. The postextension phase further confirmed durability: 18.9% of patients were seizure-free since their last extension visit at 12 weeks, and persistent responses were observed in 183 of 361 patients (50.7%), of whom 63.9% sustained a response lasting at least 48 weeks. Retrospective paediatric data reinforce these findings — among 53 TSC children treated with mTOR inhibitors, 81.1% responded, compared with 54.9% in an untreated comparator group (P = 0.004), with longer treatment duration associated with higher response rates across both early- and late-onset seizure subgroups. The safety profile across these datasets was broadly consistent, with the most frequent Grade 3–4 events including pneumonia, stomatitis, and status epilepticus; two deaths in the extension cohort were suspected to be treatment-related (pneumonia and septic shock).

Highly purified cannabidiol (CBD; Epidiolex®/Epidyolex®) has emerged as a second targeted option, now approved in the US for TSC-associated seizures in patients ≥1 year of age. A systematic review and meta-analysis encompassing six randomised controlled trials (total N = 1,034 across Dravet syndrome, Lennox-Gastaut syndrome, and TSC) demonstrated that adjunctive CBD reduces seizure frequency by 33% compared with placebo, increases the proportion of patients achieving ≥50% seizure frequency reduction by 20%, and improves caregiver/patient global impression of change in 21% of cases. These benefits were accompanied by a 16% increase in serious adverse events and a 15% increase in transaminase elevation (≥3 times the upper limit of normal) relative to placebo. The EpiCom study (NCT05864846), a Phase 3b/4 open-label trial enrolling participants aged 1–65 years across the US, UK, Canada, and Poland, is now extending the CBD evidence base beyond seizure control to evaluate behavioural and neuropsychiatric outcomes — specifically TSC-associated neuropsychiatric disorders (TAND), which affect approximately 90% of individuals with TSC — using endpoints including the Aberrant Behavior Checklist irritability subscale and the TAND-Self-Report, Quantified Checklist.

Alongside these targeted pharmacotherapies, the field is increasingly oriented toward precision medicine and preventative strategies. Vigabatrin administered pre-symptomatically has been shown to reduce the risk and severity of epilepsy, though its benefits for TAND remain inconclusive. Emerging evidence suggests that earlier deployment of mTOR-targeting agents — given that mTOR dysregulation is central to TSC pathophysiology — may prevent progression to developmental and epileptic encephalopathies such as infantile spasms syndrome or Lennox-Gastaut syndrome, though future trials are needed to confirm this. The ketogenic diet and vagus nerve stimulation remain part of the broader management toolkit, and cannabidiol's potential participation in mTOR pathway regulation is under active investigation. Collectively, the published trial data from the past five years reflect a shift from purely symptomatic seizure management toward mechanism-informed, earlier intervention strategies aimed at modifying the neurodevelopmental trajectory of TSC.

Simufilam's New Chapter: Targeting TSC-Related Epilepsy

The recent lifting of the clinical hold on simufilam for Tuberous Sclerosis Complex (TSC)-related epilepsy marks a pivotal moment for Filana Therapeutics, signaling a renewed focus for this investigational drug. With patient screening anticipated to begin by Q1 2027 for a Phase 2a proof-of-concept study, the company is poised to explore a novel therapeutic pathway for a condition with significant unmet medical needs.

TSC-related epilepsy is a particularly challenging form of epilepsy, often characterized by severe, drug-resistant seizures stemming from underlying focal cortical malformations. Current treatment options are largely symptomatic, highlighting the urgent need for therapies that can address the root causes of the disease. Simufilam, a filamin A modulator, offers a distinct mechanism of action. Preclinical research indicates that increased filamin A expression is associated with seizure activity in models of TSC and focal cortical dysplasia, and that inhibiting filamin A can reduce neuronal abnormalities and seizure frequency. This suggests simufilam could potentially offer a disease-modifying approach rather than just symptom management.

However, the path forward is not without its considerations. While simufilam (also known as PTI-125) has demonstrated a favorable safety and tolerability profile in prior clinical trials for Alzheimer's disease, those studies did not meet their primary efficacy endpoints. This raises questions about the translatability of its mechanism to complex human neurological conditions and the specific pathogenic role of filamin A in human TSC-related epilepsy. The upcoming Phase 2a study will be crucial in providing initial proof-of-concept data in a patient population aged 12 to 55, which can be particularly challenging to treat. Success in this early-stage trial would not only validate a novel mechanism but also potentially open a new therapeutic avenue for patients desperately seeking effective treatments.